Advertisement
Corrigendum
Open Access |
10.1172/JCI200847
Find articles by Lin, Y. in: PubMed | Google Scholar
Find articles by Gu, Q. in: PubMed | Google Scholar
Find articles by Lu, S. in: PubMed | Google Scholar
Find articles by Pan, Z. in: PubMed | Google Scholar
Find articles by Yang, Z. in: PubMed | Google Scholar
Find articles by Li, Y. in: PubMed | Google Scholar
Find articles by Yang, S. in: PubMed | Google Scholar
Find articles by Lv, Y. in: PubMed | Google Scholar
Find articles by Zheng, Z. in: PubMed | Google Scholar
Find articles by
Sun, G.
in:
PubMed
|
Google Scholar
|
Find articles by Gou, F. in: PubMed | Google Scholar
Find articles by Xu, C. in: PubMed | Google Scholar
Find articles by Zhao, X. in: PubMed | Google Scholar
Find articles by Wang, F. in: PubMed | Google Scholar
Find articles by
Wang, C.
in:
PubMed
|
Google Scholar
|
Find articles by
Yuan, S.
in:
PubMed
|
Google Scholar
|
Find articles by Xie, X. in: PubMed | Google Scholar
Find articles by Cao, Y. in: PubMed | Google Scholar
Find articles by Liu, Y. in: PubMed | Google Scholar
Find articles by
Gu, W.
in:
PubMed
|
Google Scholar
|
Find articles by
Cheng, T.
in:
PubMed
|
Google Scholar
|
Find articles by
Cheng, H.
in:
PubMed
|
Google Scholar
|
Find articles by Hu, X. in: PubMed | Google Scholar
Published November 17, 2025 - More info
Acute graft-versus-host disease (aGVHD) is a severe complication of allogeneic hematopoietic stem cell transplantation. Hematopoietic dysfunction accompanied by severe aGVHD, which may be caused by niche impairment, is a long-standing clinical problem. However, how the bone marrow (BM) niche is damaged in aGVHD hosts is poorly defined. To comprehensively address this question, we used a haplo-MHC–matched transplantation aGVHD murine model and performed single-cell RNA-Seq of nonhematopoietic BM cells. Transcriptional analysis showed that BM mesenchymal stromal cells (BMSCs) were severely affected, with a reduction in cell ratio, abnormal metabolism, compromised differentiation potential, and defective hematopoiesis-supportive function, all of which were validated by functional assays. We found that ruxolitinib, a selective JAK1/2 inhibitor, ameliorated aGVHD-related hematopoietic dysfunction through a direct effect on recipient BMSCs, resulting in improved proliferation ability, adipogenesis/osteogenesis potential, mitochondria metabolism capacity, and crosstalk with donor-derived hematopoietic stem/progenitor cells. By inhibiting the JAK2/STAT1 pathway, ruxolitinib maintained long-term improvement of aGVHD BMSC function. Additionally, ruxolitinib pretreatment in vitro primed BMSCs to better support donor-derived hematopoiesis in vivo. These observations in the murine model were validated in patient samples. Overall, our findings suggest that ruxolitinib can directly restore BMSC function via the JAK2/STAT1 pathway and, in turn, improve the hematopoietic dysfunction caused by aGVHD.
Yan Lin, Quan Gu, Shihong Lu, Zengkai Pan, Zining Yang, Yapu Li, Shangda Yang, Yanling Lv, Zhaofeng Zheng, Guohuan Sun, Fanglin Gou, Chang Xu, Xiangnan Zhao, Fengjiao Wang, Chenchen Wang, Shiru Yuan, Xiaobao Xie, Yang Cao, Yue Liu, Weiying Gu, Tao Cheng, Hui Cheng, Xiaoxia Hu
Original citation: J Clin Invest. 2023;133(15):e162201. https://doi.org/10.1172/JCI162201
Citation for this corrigendum: J Clin Invest. 2025;135(22):e200847. https://doi.org/10.1172/JCI200847
The authors recently became aware that the aGVHD image in Figure 9B was inadvertently duplicated from the aGVHD + vehicle image in 9D. The correct (Figure 9B) provided from the original source data is below. The HTML and PDF versions of the paper have been updated.
The authors regret the error.